Anti-tumour immune cells in mesothelioma

Mesothelioma is an aggressive cancer for which chemo- and radiotherapy are only marginally beneficial for patients. It is crucial to find new treatments which prolong survival and improve quality of life.

Dr Tabi and her team aim to investigate whether patients' own immune system can be stimulated to attack tumour cells. This would hopefully offer a relatively non-toxic treatment with no side-effects, unlike current chemo- and radio-therapies.

The outcome of this research will provide the basis for the development of a new type of treatment for mesothelioma, namely "immunotherapy". There are considerable efforts world-wide to make immunotherapy of cancer more effective in a wide range of cancers. The findings of this project will help to add mesothelioma to the list of cancers which can be considered for immune therapy.

Grant: June Hancock Fund for Mesothelioma Research Award
Duration: 36 months
Amount awarded: £138,119
Relevant disease area(s): mesothelioma
Relevant age group(s): adults